- Home
- NRIX vs BTX Comparison
NRIX vs BTX Comparison
Compare NRIX & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- BTX
- Stock Information
- Founded
- NRIX 2009
- BTX N/A
- Country
- NRIX United States
- BTX United States
- Employees
- NRIX N/A
- BTX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- BTX
- Sector
- NRIX Health Care
- BTX
- Exchange
- NRIX Nasdaq
- BTX Nasdaq
- Market Cap
- NRIX 728.6M
- BTX 854.3M
- IPO Year
- NRIX 2020
- BTX N/A
- Fundamental
- Price
- NRIX $8.97
- BTX $6.98
- Analyst Decision
- NRIX Strong Buy
- BTX
- Analyst Count
- NRIX 14
- BTX 0
- Target Price
- NRIX $29.07
- BTX N/A
- AVG Volume (30 Days)
- NRIX 847.4K
- BTX 775.7K
- Earning Date
- NRIX 10-10-2025
- BTX 11-01-2025
- Dividend Yield
- NRIX N/A
- BTX 14.38%
- EPS Growth
- NRIX N/A
- BTX N/A
- EPS
- NRIX N/A
- BTX N/A
- Revenue
- NRIX $88,381,000.00
- BTX N/A
- Revenue This Year
- NRIX $74.59
- BTX N/A
- Revenue Next Year
- NRIX N/A
- BTX N/A
- P/E Ratio
- NRIX N/A
- BTX N/A
- Revenue Growth
- NRIX 41.86
- BTX N/A
- 52 Week Low
- NRIX $8.18
- BTX $5.10
- 52 Week High
- NRIX $29.56
- BTX $8.31
- Technical
- Relative Strength Index (RSI)
- NRIX 42.73
- BTX 44.36
- Support Level
- NRIX $8.33
- BTX $6.81
- Resistance Level
- NRIX $10.13
- BTX $7.16
- Average True Range (ATR)
- NRIX 0.49
- BTX 0.10
- MACD
- NRIX -0.00
- BTX -0.01
- Stochastic Oscillator
- NRIX 35.56
- BTX 45.95
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.